Fundacion CITA Alzheimer
- Address
- Pasealeku Mikeletegi 71, 20009 Donostia / San Sebastian, Spain
Fundacion CITA Alzheimer - Specialized Alzheimer's Disease Research Center
Fundacion CITA Alzheimer is a dedicated research center specializing in comprehensive clinical investigations across the full spectrum of Alzheimer's disease, from preclinical stages through early disease manifestation. The center demonstrates particular expertise in evaluating novel therapeutic approaches targeting amyloid pathology, neuroinflammation, and cognitive preservation in diverse patient populations.
- Preclinical and early Alzheimer's disease interventions, including amyloid-targeting therapies such as BAN2401 and innovative immunotherapies
- Alzheimer's disease in special populations, particularly individuals with Down syndrome who face elevated risk for early-onset dementia
- Neuroinflammation-targeted treatments and seizure prevention strategies in Alzheimer's patients
- Long-term safety and efficacy assessments of disease-modifying therapies with extended follow-up protocols
The center conducts pivotal Phase 3 trials evaluating disease-modifying agents and maintains robust extension study programs to assess sustained treatment effects. Their research portfolio includes cutting-edge investigations into biomarker-driven patient selection, cognitive composite measures such as PACC5 and CDR-SB, and novel antisense oligonucleotide therapies. With specialized expertise in managing complex trial populations including individuals with Down syndrome, Fundacion CITA Alzheimer plays a crucial role in advancing therapeutic options for preventing and treating Alzheimer's disease across its various presentations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eisai Limited2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fundacion CITA Alzheimer
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of GSK4527226 in Early Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study | Glaxosmithkline Research & Development Limited | Phase II | Not Recruiting | May 2024 | Apr 2026 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Florquinitau (18F) | 3 | Unknown | 2021-07-21 | 2024-05-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.